No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.

Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y

Journal of clinical oncology : official journal of the American Society of Clinical Oncology23 May 2016Cited by 167 (Europe PMC)

PMID27217453DOI10.1200/jco.2015.65.8864PepBankPUB-27217453

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In lymphoma patients, adding triptorelin to norethisterone during chemotherapy did not significantly change premature ovarian failure risk.
In plain wordsIn lymphoma patients, adding triptorelin to norethisterone during chemotherapy did not significantly change premature ovarian failure risk.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePremature ovarian failure
Study
n = 67
Comparator
Norethisterone alone during chemotherapy
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
POF odds ratio
0.702 odds ratio
GnRHa coadministration
P value
0.651
GnRHa coadministration
Source sentences
Summary
but not to the coadministration of GnRHa during chemotherapy (odds ratio, 0.702; P = .651).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 129 patients with lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) during chemotherapy.
Summary · context
Sixty-seven patients 26.21 ± 0.64 years of age had available data after a median follow-up time of 5.33 years in the GnRHa group and 5.58 years in the control group (P = .452).
Report a problemFND-2721745301
02HumanRandomized controlled trialEfficacy outcome
In lymphoma patients, ovarian reserve, evaluated by anti-Müllerian hormone and follicle-stimulating hormone levels, was similar with triptorelin plus norethisterone and norethisterone alone.
In plain wordsIn lymphoma patients, ovarian reserve measured by hormone levels was similar with triptorelin plus norethisterone and norethisterone alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOvarian reserve by anti-Müllerian hormone and follicle-stimulating hormone
Study
n = 67
Comparator
Norethisterone alone during chemotherapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
The ovarian reserve, evaluated using anti-Müllerian hormone and follicle-stimulating hormone levels, was similar in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 129 patients with lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) during chemotherapy.
Summary · context
Sixty-seven patients 26.21 ± 0.64 years of age had available data after a median follow-up time of 5.33 years in the GnRHa group and 5.58 years in the control group (P = .452).
Report a problemFND-2721745302
03HumanRandomized controlled trialEfficacy outcome
In lymphoma patients, pregnancy achievement did not differ significantly between triptorelin plus norethisterone and norethisterone alone.
In plain wordsIn lymphoma patients, pregnancy achievement did not differ significantly between triptorelin plus norethisterone and norethisterone alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePregnancy achievement
Study
n = 67
Comparator
Norethisterone alone during chemotherapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Pregnancy
53%
GnRHa group
Pregnancy
43%
control group
Source sentences
Summary
Fifty-three percent and 43% achieved pregnancy in the GnRHa and control groups, respectively (P = .467).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 129 patients with lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) during chemotherapy.
Summary · context
Sixty-seven patients 26.21 ± 0.64 years of age had available data after a median follow-up time of 5.33 years in the GnRHa group and 5.58 years in the control group (P = .452).
Report a problemFND-2721745304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.